Skip to main content

Ritalin LA

(methylphenidate hydrochloride extended-release, bimodal beads)

Ritalin LA (methylphenidate hydrochloride extended-release, bimodal beads); CII

Full Prescribing Information DailyMed Drug Information

Summary

Ritalin LA is a bead-filled methylphenidate capsule carrying half its dose as immediate-release beads and half as enteric-coated delayed-release beads, reproducing a twice-daily Ritalin regimen in one morning capsule. Its approval is narrower than any other long-acting methylphenidate here: ADHD in children 6 to 12 years only. The capsule can be opened onto applesauce, so it suits a child who cannot swallow. Schedule II; brand and generic.

Forms & Strengths

  • Extended-release capsules (bimodal beads, may be opened onto applesauce): 10 mg, 20 mg, 30 mg, 40 mg, 60 mg

Dosing

  • Age: 6 to 12 y/o only; no adolescent and no adult indication
  • Onset: ~ 1 hour
  • Duration: about 8 hours
  • Release Profile: 50% IR / 50% DR via bimodal beads
  • Initial Dose:
    • New to methylphenidate: 20 mg once daily in the morning; 10 mg where a lower start is appropriate
    • From Ritalin twice daily, per dose: 5 mg to 10 mg; 10 mg to 20 mg; 15 mg to 30 mg; 20 mg to 40 mg; 30 mg to 60 mg once daily
  • Titration: 10 mg every 7 days
  • Max Dose: 60 mg/day
  • Considerations: Switching from any methylphenidate other than Ritalin means titrating from the start, not converting milligram-for-milligram. Capsules may be opened onto cool applesauce.

Pharmacology

  • Mechanism: Blocks presynaptic dopamine and norepinephrine reuptake at DAT and NET; does not meaningfully promote catecholamine release at therapeutic doses
  • Delivery / Release: 50% IR / 50% DR via bimodal beads. Enteric-coated beads release past gastric pH, giving two peaks about 4 hours apart with less fluctuation than two separate tablets.
  • Metabolism: De-esterified to ritalinic acid, inactive. Not a CYP substrate. Half-life 2.5 h in children, 3.5 h in adults. No accumulation once daily.
  • Class Positioning: Two discrete peaks, not an ascending ramp, and a shallower dip than two separate Ritalin tablets. Against Metadate CD the split is 50/50 not 30/70; against Concerta it can be sprinkled but stops at 12.
  • Cardiac electrophysiology: no QT study on this product; the dexmethylphenidate study cited found mean QTcF under 5 ms.

Indications

  • ADHD (ICD-10: F90.0, F90.1, F90.2, F90.8, F90.9): patients 6 to 12 y/o

Off-Label Uses

  • ADHD in adolescents 13 to 17 and in adults (ICD-10: F90.x): the commonest off-label use; no adolescent efficacy data. Insufficient for this product. (AHRQ 2024)
  • ADHD in children 4 to 5 years old (ICD-10: F90.x): behavioral parent training first line; if medication is needed use IR methylphenidate. Expert consensus. (AAP 2019)
  • Narcolepsy (ICD-10: G47.419): IR methylphenidate carries this indication, Ritalin LA does not. Insufficient.
  • Where the evidence does not support use: treatment-resistant depression, binge eating disorder, cancer-related and chronic fatigue. Adult literature only; insufficient in children. (AHRQ 2024)
  • Cognitive enhancement in a youth without ADHD: not an indication and not supported.

Contraindications & Warnings

  • Boxed Warning: Abuse, misuse and addiction, with overdose and death. Assess abuse risk before prescribing and reassess throughout treatment.
  • Contraindicated:
    • Hypersensitivity to methylphenidate or any component
    • MAOI use, current or within 14 days: hypertensive crisis
  • Use with caution:
    • Structural cardiac abnormality, cardiomyopathy, arrhythmia or coronary disease: avoid
    • Pre-existing hypertension: monitor blood pressure and pulse
    • Psychotic or bipolar disorder: exacerbation and treatment-emergent mania
    • Significant hyperopia or angle-closure risk: refer to ophthalmology
    • Personal or family history of tics or Tourette's syndrome
    • Substance use disorder in patient or household; beads can be crushed, so this is not abuse-deterrent
  • Screen before starting:
    • Cardiac history and exam including family sudden death; the label requires no routine ECG
    • Tics, and risk factors for a manic episode
    • Abuse and diversion risk in patient and household
    • Baseline height, weight, blood pressure and heart rate
    • Age against the 6 to 12 indication; near 13, pick an agent labeled for adolescents

Drug Interactions

  • MAOIs (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue): hypertensive crisis. Contraindicated within 14 days.
  • Antihypertensives: effectiveness reduced. Increase BP monitoring and adjust the antihypertensive.
  • Halogenated anesthetics (sevoflurane, isoflurane, desflurane): intraoperative BP and HR surge. Hold on the day of surgery.
  • Risperidone: EPS may increase when either dose changes in either direction. Monitor across any titration; a common pairing in ADHD with aggression.
  • Serotonergic agents (SSRIs, SNRIs, TCAs, triptans, tramadol): serotonin syndrome in postmarketing reports only, not in the interaction table. Counsel on symptoms.

Administration

  • Once daily in the morning; no food timing needed, and no dose dumping.
  • Swallow whole, or open onto a spoonful of applesauce that is cool, never warm; heat damages the coating on the delayed beads.
  • Swallow the applesauce mixture at once and entirely, without chewing; never prepare it in advance.
  • Do not crush, chew or divide the beads; chewing converts the whole dose to immediate release.
  • Switching from any methylphenidate other than Ritalin: titrate from the beginning, never milligram-for-milligram.
  • Missed dose: skip it; a late dose puts the delayed bead peak in the evening.
  • Store locked; an openable bead capsule is straightforward to misuse.

Side Effects

  • Common: headache, insomnia, upper abdominal pain, decreased appetite, anorexia. No pediatric percentages published.
  • Serious:
    • Sudden death with structural cardiac disease: avoid the drug in that population
    • New psychosis or mania, including with no psychiatric history: consider discontinuing
    • Priapism, sometimes surgical, typically after a dose increase and also during drug holidays
    • Peripheral vasculopathy and Raynaud's with digital ulceration: assess digits each visit
    • Long-term growth suppression; the whole indicated population is prepubertal
    • Acute angle closure glaucoma; new or worsening tics and Tourette's
    • Postmarketing: convulsions, choreoathetoid dyskinesia, cerebral vasculitis and hemorrhage, serotonin syndrome

Monitoring & Labs

  • Growth: height, weight and BMI at baseline and every 6 months, every visit if losing weight.
  • Cardiovascular: BP and HR at baseline, at every dose change, and at least every 6 months.
  • Appetite and sleep: at every visit and dose change; suppression is heaviest at the morning peak.
  • Afternoon coverage: ask at every visit about the hours after the second peak. Late-afternoon return is expected; change product rather than raise the dose.
  • Age against indication: check at every annual visit. At 13 this becomes off-label with no adolescent efficacy data; plan the switch first. Concerta is labeled to 65, Aptensio XR has no upper limit.
  • Psychiatric and tics: screen for psychosis, mania, aggression, depressed mood and tics at baseline and every visit.
  • Abuse and diversion: at every refill, capsule count, ask about sharing and selling, check the PDMP. A capsule made to be opened is not abuse-deterrent.
  • Laboratory: none is required by this label.

Discontinuation & Taper

  • No taper required; the label gives no tapering schedule.
  • Discontinue if no improvement after appropriate dose adjustment over one month.
  • Withdrawal after prolonged use: dysphoria, fatigue, vivid dreams, sleep change, increased appetite.
  • Priapism has occurred during drug holidays and on discontinuation.
  • Drug holidays are reasonable where growth limits treatment; a capsule cannot be part-dosed.
  • Switching to another methylphenidate: titrate the new product from its own starting dose.

Pregnancy & Lactation

  • Pregnancy: no drug-associated risk of major birth defects or miscarriage identified. Stimulant vasoconstriction may reduce placental perfusion. Background risk 2% to 4% and 15% to 20%.
  • Lactation: infant dose 0.16% to 0.7% of the maternal weight-adjusted dose; undetectable in infant serum in every reported case. Not a reason to stop breastfeeding. (LactMed 2025)
  • Lactation, milk supply: prolactin falls; large doses may interfere before supply is established. Monitor the infant for agitation, insomnia and poor weight gain. (LactMed 2025)
  • Exposure Registry: National Pregnancy Registry for ADHD Medications, 1-866-961-2388, womensmentalhealth.org/adhd-medications.

Counseling Points

  • Counsel the family on:

    • The applesauce rule: cool never warm, swallowed at once, never chewed, never made up in advance.
    • The two-peak pattern: a mid-morning lull is not a failed dose.
    • Coverage reaching early afternoon, not evening; if homework is the problem, this is the wrong product.
    • Giving breakfast before the capsule; the morning half is what flattens appetite.
    • Never chewing the beads; chewed beads turn a full-day dose into one immediate-release hit.
    • The 6 to 12 approval, so the plan will change in adolescence. Say it early, or the switch reads as failure.
    • Locked storage; a capsule of loose beads is easily emptied.

  • Advise them to call for:

    • Chest pain, fainting, or a racing heart that does not settle.
    • New hallucinations or suspicious thinking; eye pain with halos around lights.
    • Numbness, coldness or colour change in fingers or toes, or a sore that will not heal.
    • A new or markedly worse tic, including throat clearing and blinking.
    • A painful erection lasting more than a few hours, including during a planned break.
    • Any seizure, or a jerking movement the child cannot stop.
    • Clothes fitting more loosely, or no weight gain across a few months.

References

  1. DailyMed. Ritalin LA (methylphenidate hydrochloride) extended-release capsules prescribing information. Novartis Pharmaceuticals Corporation. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca
  2. FDA. openFDA National Drug Code Directory, generic_name methylphenidate. 2026. https://api.fda.gov/drug/ndc.json?search=generic_name:%22methylphenidate%22&limit=1000
  3. LactMed. Methylphenidate. Drugs and Lactation Database, NICHD. 2025. https://www.ncbi.nlm.nih.gov/books/NBK501310/
  4. American Academy of Pediatrics. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents. Pediatrics. 2019. https://publications.aap.org/pediatrics/article/144/4/e20192528/81590/
  5. AHRQ. Attention deficit hyperactivity disorder: diagnosis and treatment in children and adolescents. Comparative Effectiveness Review No. 267. 2024. https://www.ncbi.nlm.nih.gov/books/NBK602989/
Back to top